IIT Guwahati transfers technology for 1st recombinant vaccine for swine fever virus

Guwahati, March 26: Researchers at the Indian Institute of Technology (IIT) Guwahati on Tuesday announced the transfer of key technology for the commercial rollout of India's first recombinant vaccine for swine fever virus in pigs and wild boars.

The institute said in a statement that they have successfully transferred a pioneering vaccine technology to BioMed Pvt. Ltd., a leading manufacturing company specialising in high-quality vaccines. This technology entails a recombinant vector vaccine designed specifically for combating the classical swine fever virus in pigs and wild boars, filling a significant gap in India's vaccine landscape.

This first recombinant virus-based vaccine for pigs harnesses a reverse genetic platform pioneered and refined at IIT Guwahati.

Swine fever, a highly contagious disease among pigs, poses a severe threat with a very high mortality rate, although it does not affect humans.

In India, instances of this disease have been frequently observed in northeastern states, as well as in Bihar, Kerala, Punjab, Haryana, and Gujarat, among others.

The vaccine work was started in 2018–2019 through collaborative efforts between researchers from the Department of Biosciences and Bioengineering at IIT Guwahati and Assam Agricultural University in Guwahati.

“This vaccine is being created and produced for the first time in India. The disease poses a significant threat to India's pig industry, and currently, there is no available vaccine. Transferring the vaccine technology to one of the leaders in the veterinary vaccine sector marks a remarkable achievement,” the statement read.

Reverse genetics stands as a potent method and tool for the development of vaccines targeting both animal and human diseases. The technology has been widely used to develop vaccines against influenza.

This advancement is crucial in curbing the spread of this incurable disease among pigs across breeding farms in India, particularly in the northeast, where cases have been rampant in recent years.

“At present, the vaccine is in the process of filing a test and analysis licence,” IIT Guwahati said.